Geographic Atrophy

Latest News

Scientists sitting in lab examining results Image credit: AdobeStock/CoetzeeRising/peopleimages.com
LumiThera announces top-line results from LIGHTSITE IIIB extension trial assessing the Valeda Light Delivery System

May 13th 2025

Valeda met the primary end point in the US LIGHTSIDE III trial, improving the best corrected visual acuity in patients for 24 months of >5 letters or equivalent to 1 line improvement on the eye chart, according to the company.

Cognition Therapeutics publishes topline results of oral candidate zervimesine for the treatment of geographic atrophy - Image credit: ©Milan—stock.adobe.com
Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics

May 8th 2025

Boehringer advances 2 geographic atrophy candidates to phase 2 clinical trials - Image credit: ©Dzmitry—stock.adobe.com
Boehringer Ingelheim kicks off dual phase 2 clinical studies for geographic atrophy candidates

May 8th 2025

Topcon Healthcare acquires RetInSight - © InfiniteFlow—stock.adobe.com
Topcon Healthcare acquires RetInSight to fuel AI in retinal disease diagnosis, monitoring

May 2nd 2025

Video Series
Video Interviews
Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.